From a vaccine that requires one dose instead of two, the US authorities promise to speed up the vaccination campaign.
The FDA reported on the efficacy and safety of Johnson & Johnson on Wednesday in a report based on the results of expert studies. A panel of independent FDA experts is expected to decide on Friday whether the vaccine will be approved for emergency use in the United States.
Efficiency from 57 to 72 percent
Almost 44,000 volunteers were involved in the global study. In the United States, the substance was 72% effective, in Latin America 66%, and in South Africa, where a new coronavirus mutation spread, the efficacy was 57 percent.
Overall, the substance showed 66% efficacy against moderate to severe covid. According to the results of the study to date, the effectiveness of the vaccine against severe covid has been very high, as no hospital-related hospitalizations or deaths have been reported 28 days after its administration. The FDA reported that the vaccine also reduced the risk of infection 14 days after administration.
Side effects in three patients
According to the study, three vaccine recipients had serious side effects that were probably related to the vaccine. However, the FDA said its analysis did not raise any specific concerns about the safety of the vaccine that would prevent emergency approval.
According to the FDA, the most common side effects were injection site pain (48.6 percent), headache (39 percent), fatigue (38.2 percent), and muscle pain (33.2 percent). Nine percent of study participants reported fever, while 0.2 percent reported fever.
The Johnson & Johnson vaccine, unlike the Pfizer and Moderna vaccines, can be stored in the refrigerator for up to three months, making it easier to distribute. It was made on a similar principle to the AstraZeneca vaccine, which requires the administration of two doses. Johnson & Johnson also applied for conditional approval of its vaccine this month from the European Medicines Agency. The company’s goal is to produce about a billion batches by the end of the year.